For more information, please refer to FAQs. 

2. Increase in CPF contribution rates for senior workers

In line with the recommendations of the Tripartite Workgroup on Older Workers, the CPF contribution rates for senior workers will increase to help them save more for retirement. From January 2027, the total contribution rates will be raised by 1.5 percentage points for employees aged above 55 to 60, and 1.0 percentage point for employees aged above 60 to 65. The increase in contribution rates will be fully allocated to the CPF Retirement Account, up to their Full Retirement Sum (FRS). 

A CPF Transition Offset equivalent to half of the 2027 increase in employer CPF contributions will be provided to employers to cushion the impact on business cost. This will be provided automatically, and employers need not apply for the offset.

For more information, please refer to the FAQ. 

3. New investment scheme to be introduced in 2028 offering simplified, low-cost, and diversified commercial investment products  

In response to the CPF Advisory Panel’s recommendation for the Lifetime Retirement Investment Scheme, and following a market study, the CPF Board will introduce a new investment scheme in the first half of 2028, or earlier if possible. 

The new scheme, which will offer life-cycle investment products, will cater to long-term investors who are willing to take some risk for potentially higher returns, but who may have less expertise in navigating the CPF Investment Scheme offerings or prefer not to actively manage their investments. To simplify decision-making for investors, CPF Board will select two to three reputable product providers to offer a small number of options.  

Participation in the new scheme will be voluntary.

The CPF Board will engage the industry on the product specifications.

Further details will be announced later. 

For more information, please refer to the press release.

5 March 2026

The Ministry of Health (MOH) made the following CPF-related announcements during the FY2026 Committee of Supply Debate in Parliament on 5 March 2026.

4. Enhancements to the MediSave500/700 Scheme and Coverage of Chronic Disease Management Programme

To better support patients with chronic conditions and encourage preventive care, MOH will, from 1 January 2027, enhance the existing MediSave500/700 limits, and also rename it as the “MediSave Chronic and Preventive Care” scheme, to better reflect its purpose in supporting chronic disease management and preventive care. MOH will also expand coverage of the Chronic Disease Management Programme (CDMP).

Raising MediSave Withdrawal Limits for Chronic and Preventive Care

Under the MediSave500/700 scheme, Singaporeans can use MediSave to pay for their outpatient treatment of chronic conditions under the CDMP as well as selected vaccinations and preventive tests¹ at polyclinics, MediSave-accredited General Practitioner (GP) clinics and Specialist Outpatient Clinics. Withdrawals under the scheme are tiered, with higher annual withdrawals of $700 allowed for those with complex chronic conditions requiring more intensive management, and $500 for other patients.

To help patients better meet their chronic care and preventive care needs, MOH will raise the withdrawal limits under the MediSave Chronic and Preventive Care scheme from 1 January 2027:

a. The basic annual limit will be increased from $500 to $700; and

b. The annual limit for patients with complex chronic conditions will be increased from $700 to $1,000.

¹ These comprise (i) recommended vaccinations on the National Adult Immunisation Schedule and the National Childhood Immunisation Schedule, (ii) screening mammograms and neonatal screenings, and (iii) approved genetic tests for Familial Hypercholesterolemia at the Genomic Assessment Centres.

CDMP Extended to Hyperthyroidism and Hypothyroidism

The CDMP currently covers major chronic conditions including diabetes mellitus, hypertension, lipid disorders, stroke, and chronic obstructive pulmonary disease. To provide more comprehensive support for patients with thyroid disorders, MOH will expand the CDMP to include hyperthyroidism and hypothyroidism from January 2027.

Patients diagnosed with these thyroid conditions will be able to benefit from the higher MediSave Chronic and Preventive limit as well as receive CHAS subsidies for their ongoing treatment and management.

5. Enhancing Preventive Care through Genetic Testing for Hereditary Breast and Ovarian Cancer

Subsidies and MediSave for Genetic Testing and Downstream Interventions

Genetic testing, which reveals an individual’s pre-disposition to developing certain diseases and informs downstream management, is a key prong of Singapore’s precision medicine and preventive care strategy. MOH will extend subsidised genetic testing to Hereditary Breast and Ovarian Cancer (HBOC) from December 2026.

For the HBOC genetic test, MOH will extend subsidies and MediSave coverage:

a. Eligible Singapore Citizens and Permanent Residents can enjoy means-tested subsidies of up to 70% for these costs. Seniors from the Pioneer Generation and Merdeka Generation are eligible for additional subsidies. 

b. MediSave can be used to further offset the cost of the genetic test after subsidies, under the MediSave Chronic and Preventive Care scheme limits².

c. Patients who are 60 years old and above may also use Flexi-MediSave to further defray out-of-pocket costs fully.

Relevant downstream interventions, such as certain drug treatments and intensified surveillance, will continue to be supported with subsidies and MediSave coverage³. By ensuring affordability of these downstream interventions, MOH will support early detection and management of cancers among those who test positive for HBOC.

MOH will share more details about the financing support for the necessary genetic tests and relevant downstream interventions later this year.

² The rollout of genetic testing for HBOC is expected to be in end-2026, ahead of the implementation of the new “MediSave Chronic and Preventive” scheme from 2027. In the interim, the existing MediSave500/700 limits will similarly be extended to pay for the cost of the genetic test in end-2026.

³ At present, the MediSave Outpatient Scans limit of $600/year can be used to pay for the copayment of intensified surveillance. Additionally, seniors who are 60 years old and above may use their Flexi-MediSave limit of $400/year to pay for intensified surveillance and chemoprevention.

MediShield Life Coverage for Risk-Reducing Surgeries

For patients who test positive for HBOC and opt for risk-reducing surgeries associated with the management of HBOC, MOH is working towards implementing MediShield Life coverage for risk-reducing mastectomy by Q3 2026, with coverage for risk-reducing bilateral salpingo-oophorectomy targeted for Q4 2026. Details on the MediShield Life coverage, as well as the use of MediSave to cover the co-payment, will be shared nearer to their introduction. 

For more information about MOH’s announcements, please refer to MOH’s website.